Perioperative Efgartigimod for Thymoma and Myasthenia Gravis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

June 30, 2027

Conditions
Myasthenia Gravis
Interventions
DRUG

Efgartigimod Alfa

Efgartigimod will be administered intravenously on Day (D)1, D8, D15, and D22 at a dose of 10 mg/kg according to the patient's weight (maximum infusion dose of 1200 mg) over approximately 1 hour for a total of 4 doses. Thymectomy will be performed on Day 9.

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER